Table 2. Responses to imatinib in... | American Society of Hematology

Table 2.

Responses to imatinib in blast-crisis and accelerated phases of CML

	Overall hematologic response/CHR, %	Sustained hematologic responses, % (> 4 wk)	MCR, %	CCR, %	Median survival, mo
Myeloid blast crisis, n = 229	52/15	31	16	7	6.8
Ph⁺ ALL^*, n = 56	59/22	27	NA	NA	4.9
Accelerated phase, % (n = 181)	82/53	69	24	17	Not reached
Chronic phase after failure of IFN therapy	95% sustained CHR	95% sustained CHR	60	41	Not reached

	Overall hematologic response/CHR, %	Sustained hematologic responses, % (> 4 wk)	MCR, %	CCR, %	Median survival, mo
Myeloid blast crisis, n = 229	52/15	31	16	7	6.8
Ph⁺ ALL^*, n = 56	59/22	27	NA	NA	4.9
Accelerated phase, % (n = 181)	82/53	69	24	17	Not reached
Chronic phase after failure of IFN therapy	95% sustained CHR	95% sustained CHR	60	41	Not reached

MCR indicates major cytogenetic response; CCR, complete cytogenetic response; NA, not available; and CHR, complete hematologic response.

Also lymphoid blast crisis of CML.